Sol gel Technologies Ltd   (SLGL)
Other Ticker:  
Price: $0.8801 $0.04 4.774%
Day's High: $0.999 Week Perf: 14.3 %
Day's Low: $ 0.87 30 Day Perf: 25.73 %
Volume (M): 78 52 Wk High: $ 4.05
Volume (M$): $ 69 52 Wk Avg: $1.64
Open: $0.87 52 Wk Low: $0.63

 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Sol Gel Technologies Ltd
Sol Gel Technologies Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative topical dermatological drugs. It was founded in 1997 and is headquartered in Israel. The company's research and development efforts are directed towards providing solutions to unmet needs in therapeutic dermatology.

Sol Gel Technologies specializes in the utilization of a unique, proprietary technology called "Microencapsulation Sol-Gel," which enables the development of topical drugs with improved efficacy and enhanced safety profiles. The company's products are designed to provide superior delivery of active ingredients directly to the site of dermatological action, while ensuring effective permeation through the skin barrier.

The company's flagship product is TWINRIX, the world's first combined hepatitis A and B vaccine. It is currently approved in over 100 countries, with millions of doses supplied annually. In addition, Sol Gel Technologies has a robust pipeline of other drug candidates in various stages of development, such as Encapsulated Tazarotene for the treatment of acne and Seborrheic Dermatitis, and its dermal filler platform, which aims to provide long-lasting volume restoration.

Sol Gel Technologies has partnered with various pharmaceutical companies, including GSK, AstraZeneca, and Perrigo, to develop and market its products. The company's strong intellectual property portfolio includes over 110 patents and patent applications worldwide.

Overall, Sol Gel Technologies Ltd is a promising biopharmaceutical company that is at the forefront of developing innovative topical dermatological drugs. With its proprietary technology, strong product pipeline, and strategic partnerships, the company is well-positioned to continue to deliver innovative solutions for unmet needs in therapeutic dermatology.

   Company Address: 7 Golda Meir St Ness Ziona 7403650
   Company Phone Number: 8-9313429   Stock Exchange / Ticker: NASDAQ SLGL


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Sol-Gel and Beimei Pharma Join Forces to Uphold Acne Treatment in China, Hong Kong, Macau, Taiwan, and Israel with TWYNEO

Published Thu, May 16 2024 10:00 AM UTC

TWYNEO, developed by Sol-Gel, is a novel fixed-dose combination therapy for acne vulgaris. It combines minocycline, one of the most widely prescribed oral antibiotics for acne, with Sol-Gel's proprietary 5% benzoyl peroxide (BPO) gel. This groundbreaking dual-action formulation effectively targets both the underlying causes of acne and reduces the presence of P. acnes bacter...


Sol-Gels Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream: A Potential Game-Changer in Dermatological Treatments

Published Mon, Apr 1 2024 11:00 AM UTC

The pharmaceutical industry continues to witness groundbreaking advancements that change the landscape of medical treatments. In an exciting development, Sol-Gels Collaboration Partner has emerged as the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Zoryve Cream, a revolutionary dermatological treatment. This significant milestone promises...

Sol Gel Technologies Ltd

Major Pharmaceutical Company Sol-Gel Technologies Faces Financial Crisis in Fourth Quarter of 2023

Sol-Gel Technologies, a major pharmaceutical preparations company, recently disclosed its disastrous financial report for December 31, 2023. The company's revenue decreased by 59.979% to $1.55 million, and the shortfall per share expanded to $-1.01 compared to the previous year. This is a significant decline from the prior financial reporting period where there was no shortfall per share and revenue was $0.00 million.
In the most recent fiscal period, Sol-Gel Technologies experienced a net shortfall of $-27.238 million, which is larger than the $-14.923 million shortfall from the previous year. The company announced a shortfall of $-27.24 million and revenue of $1.55 million in the fiscal year 2023. The net shortfall per share also widened to $-1.01 from $-0.65 in the previous fiscal year, while revenue tumbled by 59.98% from $3.88 million a year ago.

Clinical Study

Sol-Gel Technologies Takes on Gorlin Syndrome with Potential Paradigm-Shifting Treatment SGT-610

Published Thu, Nov 30 2023 12:00 PM UTC

Sol-Gel Technologies Begins Phase 3 Study for SGT-610, a Potential Groundbreaking Treatment for Gorlin Syndrome
NESS ZIONA, Israel, Nov. 30, 2023 - Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a renowned dermatology company specializing in innovative therapies for severe skin conditions, has recently commenced Phase 3 testing for SGT-610, a promising new topical hedgehog i...


Sol Gel Technologies Ltd's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Sol Gel Technologies Ltd does not provide revenue guidance.

Earnings Outlook
Sol gel Technologies Ltd does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com